Philip Morris International Inc. (PMI) Inaugurates Manufacturing Facility in Italy for Potentially Reduced-Risk Products*
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) inaugurates today its first manufacturing facility for large scale production of two heated tobacco alternatives to cigarettes. The announcement was made at an event at the factory in the presence of the Italian Prime Minister Matteo Renzi. The initial annual production capacity of the factory will be approximately 30 billion units.
“Our ambition is to lead a full-scale effort to ensure that non-combustible products ultimately replace cigarettes to the benefit of adult smokers, society, our company and our shareholders. This factory is a milestone in our roadmap toward this paradigm shift,” said André Calantzopoulos, PMI’s Chief Executive Officer. “This investment underscores our strong commitment to Italy and in particular to the Bologna region, which is not only home to one of our most technologically advanced filter factories located in Zola Predosa, but which also offers great infrastructure and, most importantly, access to exceptional human talent.”
Representing an anticipated investment of approximately EUR 500 million, this state-of-the-art facility currently employs over 300 people and, when fully operational, may employ up to 600. PMI affiliates in Italy already employ over 1000 people. The pre-existing pilot plant will gradually become a training center to continue to develop PMI’s manufacturing know-how and serve as a knowledge-hub for other PMI manufacturing facilities.
PMI’s investment in the development and rigorous scientific assessment of products with the potential to present less risk of harm compared to cigarettes spans more than a decade. It encompasses a wide-range of tobacco and non-tobacco containing product platforms. The tobacco heating device iQOS, the first of these products to be commercialized in November 2014, is now sold in cities in ten countries, and PMI has plans to expand sales to key cities in an additional ten markets before the end of the year. Results of commercialization to date are encouraging. Extensive research to validate the product’s potential to present less risk of harm compared to continued cigarette smoking is well advanced with very promising results to date. Any conclusion on reduced disease risk will be based on the totality of the evidence.
Philip Morris International Inc.
Philip Morris International Inc. (PMI) is the world’s leading international tobacco company, with six of the world's top 15 international brands and products sold in more than 180 markets. In addition to the manufacture and sale of cigarettes, including Marlboro , the number one global cigarette brand, and other tobacco products, PMI is engaged in the development and commercialization of Reduced-Risk Products (“RRPs”). RRPs is the term PMI uses to refer to products with the potential to reduce individual risk and population harm in comparison to smoking cigarettes. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and industry-leading scientific substantiation, PMI aims to provide an RRP portfolio that meets a broad spectrum of adult smoker preferences and rigorous regulatory requirements. For more information, see www.pmi.com and www.pmiscience.com .
* Reduced-Risk Products (RRPs) is the term PMI uses to refer to products with the potential to reduce individual risk and population harm in comparison to smoking cigarettes.
Philip Morris International media office
T: +41 (0)58 242 4500
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
SEOUL-SEMICONDUCTOR23.3.2018 19:30 | pressemeddelelse
Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine
ELLIOTT-MANAGEMENT-CORP23.3.2018 17:07 | pressemeddelelse
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance
CO-CLOVIS-ONCOLOGY-INC23.3.2018 13:54 | pressemeddelelse
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe
CO-CLOVIS-ONCOLOGY-INC23.3.2018 13:52 | pressemeddelelse
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets
JANSSEN23.3.2018 13:48 | pressemeddelelse
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)
AITHEON23.3.2018 13:02 | pressemeddelelse
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum